tert-butyl (1-benzofuran-4-yl)carbamate | 412336-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: tert-butyl (1-benzofuran-4-yl)carbamate
• 英文别名: tert-butyl benzofuran-4-carbamate；Tert-butyl 1-benzofuran-4-ylcarbamate；tert-butyl N-(1-benzofuran-4-yl)carbamate
• CAS: 412336-05-1
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: JNWQRYMPARVORS-UHFFFAOYSA-N

物化性质

• 沸点：
  295.0±13.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (1-benzofuran-4-yl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-苯并呋喃-4-胺
  参考文献：
  名称：

  Quinazoline derivatives

  摘要：

  这项发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义；制备过程，药物组合物及其在制备用作抗侵袭剂的药物中的使用，用于包含和/或治疗固体肿瘤疾病。

  公开号：

  US20040044015A1
• 作为产物：
  描述：

  甲基2-烯丙基-3-羟基苯甲酸酯 、 苯并呋喃-4-甲酸 在 二苯基膦叠氮化物 、 三乙胺 作用下， 以 叔丁醇 为溶剂， 生成 tert-butyl (1-benzofuran-4-yl)carbamate
  参考文献：
  名称：

  Quinazoline derivatives

  摘要：

  这项发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有描述中定义的任意含义；制备过程，药物组合物及其在制备用作抗侵袭剂的药物中的使用，用于包含和/或治疗固体肿瘤疾病。

  公开号：

  US20040044015A1

文献信息

• Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src
  作者：Patrick A. Plé、Tim P. Green、Laurent F. Hennequin、Jon Curwen、Michael Fennell、Jack Allen、Christine Lambert-van der Brempt、Gerard Costello

  DOI：10.1021/jm030317k

  日期：2004.2.1

  Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.
• QUINAZOLINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1326860A1

  公开（公告）日：2003-07-16
• US6939866B2
  申请人：——

  公开号：US6939866B2

  公开（公告）日：2005-09-06
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2002030926A1

  公开（公告）日：2002-04-18

  The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R?1, n, R2 and R3¿ have any of the meanings defined in the description; process for their preparation, pharmaceutical compositions them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE 3-CYANOQUINOLINE A SUBSTITUTION BENZOFURANYLE ET LEUR UTILISATION DANS LE TRAITEMENT DE TUMEURS SOLIDES
  申请人：ASTRAZENECA AB

  公开号：WO2003047585A1

  公开（公告）日：2003-06-12

  The invention concerns the use of a quinoline derivative of the Formula I, wherein each of Z, m, R1, n and R3 have any of the meanings defined hereinbefore in the description, in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.